Measles Vaccine in HCW (MV-COVID19)

Kasr El Aini Hospital

Status and phase: Suspended; Phase 3

Conditions: Covid19

Treatments: Drug: Placebos; Drug: Measles-Mumps-Rubella Vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT04357028

N-30-2020

Details and patient eligibility

About

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV,

The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19.

We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 18-50 years old
• Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact

Exclusion criteria

• acute severe illness
• recent receipt of a blood product
• history of thrombocytopenia
• Pregnant females
• any chronic medical condition
• Any participant receiving any immune suppressive medication
• Immunocompromised staff
• Participants who have egg allergy
• Participants who care for immune compromised hosts
• Participants who test positive for COVID-19 serology prior to randomization

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

200 participants in 2 patient groups, including a placebo group

MMR vaccine

Experimental group

Description:

0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm

Treatment:

Drug: Measles-Mumps-Rubella Vaccine

Control

Placebo Comparator group

Description:

0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm

Treatment:

Drug: Placebos